Bris­tol-My­ers takes an­oth­er hit on Op­di­vo/Yer­voy com­bo as CHMP turns thumbs down on front­line kid­ney can­cer

Bris­tol-My­ers Squibb $BMY con­tin­ues to run in­to some stiff head­winds with its com­bi­na­tion of Op­di­vo and Yer­voy.

Dur­ing their quar­ter­ly call with an­a­lysts Thurs­day, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER